natgillin/translations-raw huggingface dataset:
Amlodipin, diltiazem, nifedipin Ritonavir doseret som en farmakokinetisk forstærker eller som et antiretroviralt stof hæmmer CYP3A4 og forventes som følge heraf at øge plasmakoncentrationerne af kalciumantagonister.
Amlodipine, diltiazem, nifedipine Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of calcium channel antagonists.
amlodipin, felodipin, nifedipin, nicardipin, digoxin, diltiazem – anvendes mod forhøjet blodtryk og visse hjertelidelser quetiapin – anvendes til visse sindslidelser, fx skizofreni, bipolare affektive sindslidelser (manio-depressiv sygdom) og moderat til svær depression.
amlodipine, felodipine, nifedipine, nicardipine, digoxin, diltiazem - used for high blood pressure and some heart problems. quetiapine – used for some mental illnesses such as schizophrenia, bipolar disorder and major depressive disorder
amlodipin, ranolazin – bruges til at behandle angina pectoris
amlopidine, ranolazine – used to treat angina pectoris
Amlodipin/valsartan er kontraindiceret hos patienter med alvorligt nedsat leverfunktion (se pkt.
Amlodipine/valsartan is contraindicated in patients with severe hepatic impairment (see section 4.3).
Amlodipin/valsartan skal anvendes med forsigtighed ved behandling af hypertension hos patienter med unilateral eller bilateral nyrearteriestenose eller stenose i en enkelt nyre, da blod-urea og serum- kreatinin kan stige hos disse patienter.
Amlodipine/valsartan should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients.
Amlodipin/valsartan/hydrochlorthiazid
Amlodipine/valsartan/hydrochlorothiazide
Amlodipin:
Amlodipine
amlodipine, digoxin, diltiazem, disopyramid, felodipin, flecainid, systemisk lidocain, metoprolol, mexiletin, nicardipin, nifedipin, propafenon, timolol og verapamil, lægemidler, der anvendes til at behandle hjerteproblemer
amlodipine, digoxin, diltiazem, disopyramide, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nicardipine, nifedipine, propafenone, timolol and verapamil, medicines used to treat heart problems
Amlodipine/Valsartan Mylan 10 mg/160 mg filmovertrukne tabletter
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets
Amlodipine/Valsartan Mylan 10 mg/160 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt kontrolleret med amlodipin 10 mg eller valsartan 160 mg alene eller med Amlodipine/Valsartan Mylan 5 mg/160 mg.
Amlodipine/Valsartan Mylan 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Amlodipine/Valsartan Mylan 5 mg/160 mg.
Amlodipine/Valsartan Mylan 10 mg/160 mg tabletter er lysebrune, ovale, bikonvekse filmovertrukne tabletter mærket med “AV3” på den ene side og “M” på den anden side.
Amlodipine/Valsartan Mylan 10 mg/160 mg tablets are light brown, oval, biconvex film-coated tablet marked with “AV3” on one side and “M” on the other side.
Amlodipine/Valsartan Mylan 5 mg/160 mg filmovertrukne tabletter
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets
Amlodipine/Valsartan Mylan 5 mg/160 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt kontrolleret med amlodipin 5 mg eller valsartan 160 mg alene.
Amlodipine/Valsartan Mylan 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.
Amlodipine/Valsartan Mylan 5 mg/160 mg tabletter er gule, ovale, bikonvekse filmovertrukne tabletter mærket med “AV2” på den ene side og “M” på den anden side.
Amlodipine/Valsartan Mylan 5 mg/160 mg tablets are yellow, oval, biconvex film-coated tablet marked with “AV2” on one side and “M” on the other side.
Amlodipine/Valsartan Mylan 5 mg/80 mg filmovertrukne tabletter
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets
Amlodipine/Valsartan Mylan 5 mg/80 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt kontrolleret med amlodipin 5 mg eller valsartan 80 mg alene.
Amlodipine/Valsartan Mylan 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Amlodipine/Valsartan Mylan og ældre patienter (65 år og derover)
Amlodipine/Valsartan Mylan and older people (age 65 years or over)
Amlodipine/Valsartan Mylan sammen med mad og drikke
Amlodipine/Valsartan Mylan with food and drink
Amlodipins blodtrykssænkende virkning øger den blodtrykssænkende virkning af andre antihypertensive lægemidler.
The blood pressure lowering effects of amlodipine add to the blood pressure lowering effects of other antihypertensive medicinal products.
Amlodipins blodtrykssænkende virkning øger den blodtrykssænkende virkning af andre antihypertensive lægemidler.
The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other antihypertensive medicinal products.
Amlodipins farmakokinetik er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion; der skal derfor udvises forsigtighed, hvis Rasilamlo administreres til patienter med nesat leverfunktion.
The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment; therefore, caution should be exercised when administering Rasilamlo to patients with hepatic impairment.
Amlodipins virkning på andre lægemidler
Effects of amlodipine on other medicinal products
amme eksponering som en
provide exposure similar to a
ammen med
associated with
ammen med
co-administered with
ammen med andre lægemidler (tillægsbehandling) mod epilepsi til behandling af:
with other antiepileptic medicines (add-on therapy) to treat:
ammen med både metformin og et sulfonylurinstof hos patienter, som ikke reguleres tilfredsstillende, selv om de tager to lægemidler gennem munden sammen med insulin, til patienter, som ikke er tilfredsstillende reguleret med insulin alene, og som ikke kan tage metformin.
together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite treatment with two medicines by mouth; together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
ammen med dexamethason over VELCADE som monoterapi.
VELCADE in combination with dexamethasone over VELCADE monotherapy.
ammen med efavirenz 600
Integrase strand transfer inhibitor
ammen med et sulfonylurinstof og metformin (som tredobbelt behandling), når patienternes sukkersyge ikke kan kontrolleres tilfredsstillende med disse lægemidler samt diæt og motion, sammen med insulin (med eller uden metformin) til patienter, når patienternes sukkersyge ikke kan kontrolleres tilfredsstillende med diæt, motion og en fast dosis insulin.
together with a sulphonylurea and metformin (triple therapy) in patients whose diabetes is not sufficiently controlled by these medicines plus diet and exercise; together with insulin (with or without metformin) in patients whose diabetes is not sufficiently controlled by diet and exercise plus a stable dose of insulin.
ammen med kræftbehandlinger, der indeholder irinotecan sammen med behandlingen FOLFOX4, der indeholder oxaliplatin, til ikke tidligere behandlede patienter alene, når den tidligere behandling med oxaliplatin og irinotecan ikke har virket, og patienten ikke kan behandles med irinotecan.
together with anticancer treatments containing irinotecan; together with the oxaliplatin-containing treatment FOLFOX in patients who have not been treated before; on its own when previous treatment containing oxaliplatin and irinotecan has failed and the patient cannot receive irinotecan.
ammen med lavdosis ritonavir er
with a low dose ritonavir, it should
ammen med lavdosis ritonavir og
low dose ritonavir and atazanavir
ammen med lavdosis ritonavir og
PREZISTA co-administered with low dose ritonavir, dose adjustment
ammen med lavdosis ritonavir og protonpumpehæmmere uden dosisjusteringer.
PREZISTA co-administered with low dose ritonavir can be co-administered with proton pump inhibitors without dose adjustments.
ammen med lægemidlerne melphalan og prednison til behandling af patienter, der ikke tidligere er blevet behandlet for sygdommen, og som ikke er egnede til højdosiskemoterapi med transplantation af blodstamceller. sammen med lægemidlerne dexamethason eller dexamethason sammen med thalidomid til patienter, hvis sygdom ikke tidligere er blevet behandlet, og før de får højdosis-kemoterapi med transplantation af blodstamceller (induktionsbehandling).
in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation. in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).
ammen med metformin, et thiazolidindion eller et sulfonylurinstof (som dobbelt behandling), når patientens sukkersyge ikke kan kontrolleres tilfredsstillende med denne anden medicin alene, men det anvendes kun i kombination med et sulfonylurinstof til patienter, som ikke kan tage metformin,
together with metformin, a thiazolidinedione or a sulphonylurea (dual therapy) when the patient’s diabetes is insufficiently controlled by this other medicine taken alone, but it is only used in combination with a sulphonylurea in patients who cannot take metformin;
ammen med metformin, et thiazolidindion eller et sulfonylurinstof (som dobbelt behandling), når patientens sukkersyge ikke kan kontrolleres tilfredsstillende med denne anden medicin alene. men det anvendes kun i kombination med et sulfonylurinstof til patienter, som ikke kan tage metformin,
together with metformin, a thiazolidinedione or a sulphonylurea (dual therapy) when the patient’s diabetes is insufficiently controlled by this other medicine taken alone, but it is only used in combination with a sulphonylurea in patients who cannot take metformin;
ammen med voriconazol,
co-administered with
ammen med voriconazol, bør
co-administered with
ammenbidte kæber
contraction of the jaw muscle
Ammende kvinder
Breast-feeding mothers
Ammende kvinder (se pkt.
Breastfeeding women (see section 4.6)
Ammende kvinder må derfor ikke få teriflunomid.
Breast-feeding women must, therefore, not receive teriflunomide.
Ammende kvinder må ikke tage Kaletra uden lægens specifikke anvisning.
Breast-feeding mothers should not take Kaletra unless specifically directed by the doctor.
Ammende kvinder må ikke tage lopinavir/ritonavir uden lægens specifikke anvisning.
Breast-feeding mothers should not take lopinavir/ritonavir unless specifically directed by the doctor.
Ammende kvinder.
Breast-feeding women.
Ammende mødre skal afbryde amningen i 24 timer efter behandling med denne medicin.
Breast-feeding mothers should not breast- feed for 24 hours after treatment with this medicine.
Ammende mødre til nyfødte børn, der behandles med caffeincitrat, bør ikke indtage caffeinholdige mad- og drikkevarer eller lægemidler, der indeholder caffein.
Breast-feeding mothers of newborn infants treated with caffeine citrate should not ingest caffeine- containing foods, beverages or medicinal products containing caffeine.
ammenlignelig intensitet af kemoterapibehandlingen i grupperne med epoetin alfa og placebo i kemoterapistudier blev vist ved et sammenligneligt areal under neutrofil-tid-kurven hos patienter i behandling med epoetin alfa og patienter i placebogruppen, samt ved en sammenlignelig andel af patienter i epoetin alfa-gruppen og placebogruppen, hvor det absolutte neutrofiltal faldt til under 1.000 og 500 celler/µl.
Comparable intensity of chemotherapy in the epoetin alfa and placebo groups in the chemotherapy trials was demonstrated by a similar area under the neutrophil time curve in patients treated with epoetin alfa and placebo-treated patients, as well as by a similar proportion of patients in groups treated with epoetin alfa and placebo-treated groups whose absolute neutrophil counts fell below 1,000 and 500 cells/µl.
ammenlimning af væv
gluing tissues together
ammensnævring i halsen generel kløe.
throat tightness generalized itching
ammensnørende fornemmelse og irritation i halsen, hoste
throat tightness, throat irritation, cough
ammensnøring af halsen, hæs stemme eller synkebesvær
tightness of the throat, hoarse voice or trouble swallowing
ammensnøring af musklerne i luftvejene, som forårsager hvæsende vejrtrækning (bronkospasme), inflammation (betændelseslignende reaktion), irritation i lungerne, halsen eller bihulerne, åndenød, løbende næse
tightening of the muscles in the airways which causes wheezing (bronchospasm), inflammation, irritation in the lungs, throat or sinuses, being short of breath, runny nose
ammensnørret hals, næseblod
throat tightness, nose bleeds
ammentrækning af bronkierne og anafylaksi (en alvorlig allergisk reaktion, der rammer hele kroppen), vedvarende hoste,
bronchoconstriction and anaphylaxis (a severe, whole-body allergic reaction), constant cough,
ammentrækning af kæbemusklen
contraction of the jaw muscle
ammer.
are breast-feeding
AMMONAPS 500 mg tabletter
AMMONAPS 500 mg tablets
AMMONAPS 940 mg granulat
AMMONAPS 940 mg/g granules
Ammonaps blev godkendt på "særlige omstændigheder", da der på godkendelsestidspunktet kun forelå sparsomme oplysninger som følge af sygdommens sjældenhed.
Ammonaps was authorised under ‘Exceptional Circumstances’, because, as the disease is rare, limited information was available at the time of approval.
AMMONAPS skal kombineres med en lavproteindiæt, som udarbejdes specielt til dig af en læge eller en kostvejleder.
AMMONAPS must be combined with a diet reduced in proteins designed especially for you by the doctor and the dietician.
Ammoniak er specielt giftigt for hjernen, og fører i alvorlige tilfælde til bevidsthedsforstyrrelser og koma.
Ammonia is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma.
Ammoniak, dannet ved bakteriel hydrolyse, som tidligere beskrevet, metaboliseres i form af NH +.
Ammonia which is produced as described above by the bacterial hydrolysis is included into the metabolism as NH +.
Ammoniummethacrylat copolymer (type B) Calciumhydrogenphosphatdihydrat Lactosemonohydrat
Ammonio methacrylate copolymer type B Calcium hydrogen phosphate dihydrate Lactose monohydrate
Amnesi
Amnesia Aphasia
Amnesi
disorders
amnesi (hukommelsestab), hukommelsessvækkelse (glemsomhed), koordinationsbesvær, paræstesi (prikkende, snurrende fornemmelser eller følelsesløshed i huden), opmærksomhedsforstyrrelser (koncentrationsbesvær);
amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
amnesi (hukommelsestab), hukommelsessvækkelse (glemsomhed), koordinationsbesvær, paræstesi (prikkende, snurrende fornemmelser eller følelsesløshed i huden), opmærksomhedsforstyrrelser (koncentrationsbesvær);
amnesia (loss of memory),memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
amnesi (hukommelsestab), hukommelsessvækkelse (glemsomhed), koordinationsbesvær/ataksi (svækket koordination af bevægelser), prikkende fornemmelse (paræstesi) opmærksomhedsforstyrrelser (manglende koncentration)
amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
amnesi (hukommelsestab), hukommelsessvækkelse (glemsomhed), koordinationsbesvær/ataksi(/usikre bevægelser), paræstesi (prikkende, snurrende fornemmelser eller følelsesløshed i huden), opmærksomhedsforstyrrelser (koncentrationsbesvær);
amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
Amnesi Afasi
Amnesia Aphasia
Amnesi, hukommelses- svækkelse, koordinations- forstyrrelser/ataks i, paræstesi, opmærksomheds- forstyrrelser
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention
Amnesi, hukommelses- svækkelse, koordinations- forstyrrelser/ataksi, paræstesi, opmærksomheds- forstyrrelser
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia,disturbance in attention
Amnesi, hukommelsessvækkelse, koordinationsforstyrrelser/ ataksi, paræstesi, opmærksomhedsforstyr- relser
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention
Amnesi, karpaltunnelsyndrom, kognitiv forstyrrelse, opmærksomhedsforstyrrelse, postural svimmelhed, dysgeusi, hypersomnia, hypæstesi, letargi, hukommelsessvækkelse, migræne, perifer neuropati, paræstesi, døsighed, spændingshovedpine, tremor, dårlig søvnkvalitet
amnesia, carpal tunnel syndrome, cognitive disorder, disturbance in attention, dizziness postural, dysgeusia, hypersomnia, hypoaesthesia, lethargy, memory impairment, migraine, neuropathy peripheral, paraesthesia, somnolence, tension headache, tremor, poor quality sleep
Amnesi, svigtende hukommelse, synkope, migræne, ataksi, paræstesi, dysfoni, tab af smagssans, hypoæstesi, hyperæstesi, hypertoni, døsighed, opmærksomhedsforstyrrelser, tremor, smagsforstyrrelser
Amnesia, memory impairment, syncope, migraine, ataxia, paraesthaesia, dysphonia, taste loss, hypoaesthesia, hyperaesthesia, hypertonia, somnolence, disturbance in attention, tremor, dysgeusia
Amnesi, svigtende hukommelse, synkope, migræne, ataksi, tremor, paræstesi, dysfoni, tab af smagssans, hypoæstesi, hyperæstesi, hypertoni, somnolens, opmærksomhedsforstyrrelser, tremor, smagsforstyrrelser
Amnesia, memory impairment, syncope, migraine, ataxia, paraesthaesia, dysphonia, taste loss, hypoaesthesia, hyperaesthesia, hypertonia, somnolence, disturbance in attention, tremor, dysgeusia
Amnesi1, dyskinesi, hyperkinesi1, somnolens (søvnlignende bevidsthedssvækkelse), pludseligt opstået søvn, synkope
amnesia1, dyskinesia, hyperkinesia1, sudden onset of sleep, syncope
Amnesi9
Dysarthria
Amnesi9
dyskinesia11
Amning
Bre ast-feeding
Amning
Breast feeding
Amning
Breast –feeding
Amning
Breast-feeding.
Amning
Breast-feeding:
Amning
Breast-feeding¨
Amning
Breast­feeding
Amning
Fertility
Amning (se pkt.
Breast-feeding (see section 4.6)
Amning (se pkt.
Breastfeeding (see section 4.6)
Amning anbefales ikke ved indtagelse af INCRELEX.
Breast-feeding while taking INCRELEX is not recommended.
Amning bør afbrydes under behandling med Akynzeo og i 1 måned efter den sidste dosis.
Breast-feeding should be discontinued during treatment with Akynzeo and for 1 month after the last dose.
Amning bør afbrydes under behandling med Tagrisso.
Breast-feeding should be discontinued during treatment with TAGRISSO.
Amning bør dog ophøre på grund af de potentielle alvorlige bivirkninger hos børn.
However, because of the potential for serious adverse reactions in infants, breastfeeding should be discontinued.
Amning bør undlades under behandling og i fem måneder efter behandling.
Breast-feeding should be discontinued during and up to five months after treatment.
Amning frarådes under behandling med EXJADE.
Breast-feeding while taking EXJADE is not recommended.
Amning frarådes under behandling med ISENTRESS.
Breastfeeding is not recommended while taking ISENTRESS.
Amning frarådes under behandling med natriumoxybat.
Breastfeeding is not recommended during treatment with sodium oxybate.
Amning frarådes under behandling med Tasigna.
Breast-feeding is not recommended during treatment with Tasigna.
Amning frarådes, mens du tager Keytruda.
Do not breast-feed while taking KEYTRUDA.
Amning kan derfor overvejes hos ammende mødre i behandling med lamivudin mod HBV under hensyntagen til fordele ved amning for barnet samt fordele ved behandling for moderen.
Therefore breastfeeding may be considered in breast- feeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Amning kan derfor overvejes hos ammende mødre i behandling med lamivudin mod HBV under hensyntagen til fordele ved amning for barnet samt fordele ved behandling for moderen.
Therefore, breastfeeding may be considered in breast- feeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Amning kan derfor overvejes hos mødre i behandling med lamivudin mod HBV under hensyntagen til fordele ved amning for barnet samt fordele ved behandling for moderen.
Therefore breastfeeding may be considered inbreast- feeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Amning skal afbrydes i 12 timer efter anvendelse af Ameluz.
Breast-feeding should be interrupted for 12 hours after application of Ameluz.
Amning skal afsluttes inden behandlingen.
Breast-feeding should be terminated prior to treatment.
Amning skal derfor ophøre under behandling med thalidomid.
Therefore breast-feeding should be discontinued during therapy with thalidomide.
Amning skal derfor undgås.
Breast- feeding must therefore be avoided.
Amning skal ophøre i mindst 4 dage efter applikation af NexoBrid.
Breast-feeding should be discontinued for at least 4 days after NexoBrid application.
Amning skal ophøre under behandling med asfotase alfa.
Breast-feeding should be discontinued during treatment with asfotase alfa.
Amning skal ophøre under behandling med dette lægemiddel.
Breast-feeding should be discontinued during treatment with this medicine.
Amning skal ophøre under behandling med Lonquex.
You should therefore interrupt breast-feeding during treatment..
Amning skal ophøre under behandling med ofatumumab og i 12 måneder efter behandlingen.
Breastfeeding should be discontinued during treatment with ofatumumab and for 12 months following treatment.
Amning skal ophøre under behandlingen med Iclusig.
Stop breast-feeding during treatment with Iclusig.
Amning skal ophøre ved initiering af behandling med Voriconazole Hospira.
Breast-feeding must be stopped on initiation of treatment with Voriconazole Hospira.
Amning skal ophøreunder behandling med pemetrexed (se pkt.
Breast-feeding must be discontinued during pemetrexed therapy (see section 4.3).
Amning.
Breast-feeding
Amning.
Breast-feeding.
Amning.
Breastfeeding
Amning.
Lactation.
Amning:
Breast-feeding
Amning: Det vides ikke, om bexaroten udskilles i modermælk.
Breast-feeding: it is unknown whether bexarotene is excreted in human milk.
Amning: Kvinder, der tager Axura, bør ikke amme.
Breast-Feeding: Women taking Axura should not breast-feed.
Amning: Kvinder, der tager Memantine Merz, bør ikke amme.
Breast-Feeding: Women taking Memantine Merz should not breast-feed.
Amning;
Lactation
Amningen bør ophøre, hvis der gives Mirapexin.
However, if its use is unavoidable, breast-feeding should be discontinued.
Amningen bør ophøre, hvis der gives Oprymea.
However, if its use is unavoidable, breast-feeding should be discontinued.
Amningen bør ophøre, hvis der gives Pramipexole Accord.
However, if its use is unavoidable, breast-feeding should be discontinued.
Amningen bør ophøre, hvis der gives Sifrol.
However, if its use is unavoidable, breast-feeding should be discontinued.
Amningen kan fortsættes under vaccinationsprogrammet.
Therefore, breast-feeding may be continued during the vaccination schedule.
Amodiaquin og chloroquin (anvendes til behandling af malaria og nogle former for inflammation),
amodiaquine and chloroquine (used to treat malaria and some forms of inflamamtion),
Amorf aluminiumhydroxyphosphatsulfat er tilsat vaccinen som et adjuvans.
Amorphous aluminium hydroxyphosphate sulphate is included in the vaccine as an adjuvant.